HIV-1
Conditions
Brief summary
The objective of this prospective study is to evaluate the prevalence of neurocognitive impairments in HIV infected patients comparing patients with and without HAART. Recent studies have demonstrated a specific HIV infected patients neurocognitive disorders profile. These cognitive disorders concern primarily information processing speed, memory recall, attentional abilities, work related memory, executive functions, and psychometrical speed. This cognitive profile is similar to another highly documented one, described for another central nervous system disease (CNS): multiple sclerosis. In both CNS diseases, the earliest and most severe disorder is the one related to the information processing speed. For the multiple sclerosis patients, a short cognitive test (SDMT) is actually used not only to identify cognitive disorders presence, but also in order to predict a long term disability worsening. A digital version of this test (CSCT), has recently been developed in order to make this early evaluation easier. We hypothesize that CSCT alteration would also predict HAND, in HIV infected patients. A complete neuropsychological assessment is highly time and personal consuming. This short (approximatively 2 minutes) digital test would be highly helpful to identify patients, who will need a more extensive neuropsychological assessment.
Interventions
OTHERClassic evaluation of neurocognitive functions
Symbol Digit Modalities Test (SDMT)
OTHERNew evaluation of neurocognitive functions
Cognitive Speed Computerized Test (CSCT)
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients infected with HIV-1 * Patients followed in outpatient service, over 18 years of age
Exclusion criteria
* Patients infected with HIV-2 * Patients with difficulty understanding the French language * Patients present with progressive opportunistic infection * Patients for whom a change of psychotropic treatment was performed in the last 3 weeks * Patients with drug and / or alcohol addiction * Patients with a history of psychiatric disorder * Patients with stroke, endocarditis or meningoencephalitis with severe neurological sequelae
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive Speed Computerized Test (CSCT) score | at patient inclusion | allows the evaluation of the speed of the processing of the information |
| Montreal Cognitive Assessment (MoCA) Score | at patient inclusion | allows the evaluation of the overall cognitive functioning |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Score RL-RI16 | at patient inclusion | allows the evaluation of episodic and long-term verbal memory |
| Rey figure | at patient inclusion | allows the evaluation of the long-term capacities of visio-construction (wealth score) and planning |
| Paced Auditory Serial Addition Test (PASAT) score | at patient inclusion | allows to evaluate the concentration capacity |
| Verbal fluency test | at patient inclusion | allows the evaluation of the verbal initiation and verbal language capacities |
| IADL score | at patient inclusion | allows to evaluate the symptomatic character of the disorders |
| TMTB - TMTA Time Score | at patient inclusion | Assessment of Mental Flexibility |
| Numeric Memory (WAIS-III location and back) | at patient inclusion | short-term memory evaluation and verbal working memory |
Countries
France
Outcome results
None listed